First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Trading 0.6% Higher – Here’s Why

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)’s share price traded up 0.6% during trading on Monday . The company traded as high as $33.91 and last traded at $33.94. 1,276 shares traded hands during trading, a decline of 70% from the average session volume of 4,292 shares. The stock had previously closed at $33.73.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

The company has a market capitalization of $22.06 million, a PE ratio of 14.51 and a beta of 0.54. The stock’s 50 day simple moving average is $33.00 and its 200-day simple moving average is $29.91.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Friday, December 12th were paid a dividend of $0.1294 per share. This represents a $0.52 annualized dividend and a yield of 1.5%. The ex-dividend date of this dividend was Friday, December 12th.

Hedge Funds Weigh In On First Trust Nasdaq Pharmaceuticals ETF

Several institutional investors have recently modified their holdings of FTXH. Goldman Sachs Group Inc. raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 11.7% in the first quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock valued at $535,000 after acquiring an additional 2,047 shares in the last quarter. Bank of Montreal Can increased its holdings in First Trust Nasdaq Pharmaceuticals ETF by 68.2% during the 2nd quarter. Bank of Montreal Can now owns 8,221 shares of the company’s stock worth $211,000 after purchasing an additional 3,333 shares during the period. Summit Investment Advisors Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 8.1% in the 1st quarter. Summit Investment Advisors Inc. now owns 15,320 shares of the company’s stock valued at $421,000 after purchasing an additional 1,147 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF by 2.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 15,711 shares of the company’s stock valued at $403,000 after purchasing an additional 391 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of First Trust Nasdaq Pharmaceuticals ETF in the 2nd quarter valued at about $57,000.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.